During a career of nearly 30 years with Gilead, Bischofberger oversaw the development of more than 25 medicines that transformed the treatment of serious pathogens or diseases including HIV, HCV and lymphoma.
Bischofberger currently serves as the president and chief executive officer of Kronos Bio, a developer of novel therapies targeting historically recalcitrant cancer targets.
Prior to Kronos, he served as a scientific leader for 28 years at Gilead Sciences, concluding his tenure as chief scientific officer and executive vice president of research and development. Prior to Gilead, he served as a senior research scientist at Genentech.
Bischofberger also currently serves on the Supervisory board of Bayer AG and board of directors of InCarda Therapeutics.
He is an elected Fellow of the American Association for Advancement of Science and was awarded an honorary doctorate in natural sciences from the University of Innsbruck, where he earned his Bachelor of Science in chemistry.
He also holds an honorary Doctor of Letters in Medicine degree from Baylor College of Medicine. Dr. Bischofberger earned his Ph.D. in organic chemistry from ETH Zurich (Eidgenössische Technische Hochschule) and completed postdoctoral research in organic chemistry and applied enzymology at George Whiteside's laboratory at Harvard University.
Morphic Therapeutic is a biotechnology company developing a new generation of oral integrin therapies.
Drawing on integrin biology breakthroughs from the lab of noted entrepreneur and scientific founder Tim Springer, Morphic has developed an exclusive platform to build on these discoveries, complemented by a partnership with computational chemistry leader Schrödinger, Inc., that facilitates the rapid and iterative design of clinical candidates.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval